PBS updates

Xalkori (Crizotinib)

crizotinib 250 mg capsule, 60 · ORAL · PBS code 10322G

AUTHORITY_REQUIRED

What it costs

AU$6433.3 PBS-determined price per 60 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

  • • First listed on the PBS: 2015-07-01.
  • • Repeats: 3.
  • • PBS program: GE.
Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC)


Initial treatment


The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition; AND

The condition must be non-squamous type non-small cell lung cancer (NSCLC) or not otherwise specified type NSCLC; AND

Patient must have a WHO performance status of 2 or less; AND

Patient must have evidence of an anaplastic lymphoma kinase (ALK) gene rearrangement in tumour material, defined as either: (i) 15% (or greater) positive cells by fluorescence in situ hybridisation (FISH) testing, (ii) positive next generation sequencing (NGS) testing; AND

Must be treated by a medical practitioner.

Applications for authorisation of initial treatment must be made via the Online PBS Authorities System (real time assessment) or in writing via HPOS form upload or mail.

If the application is submitted through HPOS form upload or mail, it must include:

(a) details of the proposed prescription; and

(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).

The following must be documented in the patient's medical records:

(a) evidence of an anaplastic lymphoma kinase (ALK) gene rearrangement in tumour material.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC)


Continuing treatment


The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition; AND

Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND

Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition; AND

Must be treated by a medical practitioner; or

Must be treated by a nurse practitioner where both of the following are occurring: (i) patient care is being shared with a medical practitioner, (ii) the prescription continues existing therapy with this medicine.

Sponsor: Pfizer Australia Pty Ltd ABN 50 008 422 348

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.